← 產業報告目錄
Trastuzumab Biosimilar Market Size, Share & Trends Analysis Report By Product (Ogivri, Herzuma, Ontruzant, Trazimera, Other Pipeline Products), By Indication, By Route of Administration, By Molecule Type, Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-07頁數 180報告編號 INSIGHTACE-7d55a7115d
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
A CAGR of 25.0% is forecasted for the global Trastuzumab Biosimilar Market over the assessment period of 2025 through 2034.
The Trastuzumab Biosimilar sector involves a recombinant dna-derived humanized monoclonal antibody that binds to human epidermal growth factor receptor 2 (her2). This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the expanding emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1.Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2.Executive Summary
Chapter 3.Global Trastuzumab Biosimilar Market Snapshot
Chapter 4.Global Trastuzumab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Key Trends in the Market
4.5. Clinical Trial/Pipeline Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Historic Revenue of Originator Brand (Herceptin) 2011-2019
4.8. Technology Advancement and Key Funding Activities in Trastuzumab Biosimilar Market
4.9. Impact of COVID -19 on Pharmaceutical Industry
Chapter 5.Market Segmentation 1: Product Estimates & Trend Analysis
5.1. Product Type & Market Share, 2024-2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Ogivri
5.2.2. Herzuma
5.2.3. Ontruzant
5.2.4. Trazimera
5.2.5. Other Pipeline Products
Chapter 6.Trastuzumab Biosimilar Market Segmentation 2: Indication Type Estimates & Trend Analysis
6.1. Indication Type Analysis & Market Share, 2024-2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication Type:
6.2.1. Adjuvant Breast Cancer
6.2.2. Metastatic Breast Cancer
6.2.3. Metastatic Gastric Cancer
6.2.4. Other Indication
Chapter 7.Trastuzumab Biosimilar Market Segmentation 3: Route of Administration Estimates & Trend Analysis
7.1. Indication Type Analysis & Market Share, 2024-2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication Type:
7.2.1. Subcutaneous
7.2.2. Intravenous
7.2.3. Parenteral
7.2.4. Molecule Type
Chapter 8.Trastuzumab Biosimilar Market Segmentation 4: Molecule Type Estimates & Trend Analysis
8.1. Indication Type Analysis & Market Share, 2024-2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication Type:
8.2.1. Monoclonal antibodies
8.2.2. Peptide
8.2.3. Protein
8.2.4. Small molecule
8.2.5. Product Type
Chapter 9.Trastuzumab Biosimilar Market Segmentation 5: Distribution Channel Estimates & Trend Analysis
9.1. Distribution Channel Analysis & Market Share, 2024-2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
9.2.1. Hospital Pharmacy
9.2.2. Online and Retail Pharmacy
9.2.3. Other Direct Distribution Channels
Chapter 10.Trastuzumab Biosimilar Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Product, 2021-2034
10.1.2. North America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034
10.1.3. North America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
10.1.4. North America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule Type, 2021-2034
10.1.5. North America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channel, 2021-2034
10.1.6. North America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
10.1.6.1.U.S.
10.1.6.2.Canada
10.2. Europe
10.2.1. Europe Trastuzumab Biosimilar Market revenue (US$ Million) by Product, 2021-2034
10.2.2. Europe Trastuzumab Biosimilar Market revenue (US$ Million) by Indication Type, 2021-2034
10.2.3. Europe Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
10.2.4. Europe Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule Type, 2021-2034
10.2.5. Europe Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channel, 2021-2034
10.2.6. Europe Trastuzumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
10.2.6.1.Germany
10.2.6.2.Poland
10.2.6.3.France
10.2.6.4.Italy
10.2.6.5.Spain
10.2.6.6.UK
10.2.6.7.Rest of Europe
10.3 Asia Pacific
10.3.1. Asia Pacific Trastuzumab Biosimilar Market revenue (US$ Million) by Product, 2021-2034
10.3.2. Asia Pacific Trastuzumab Biosimilar Market revenue (US$ Million) by Indication Type, 2021-2034
10.3.3. Asia Pacific Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
10.3.4. Asia Pacific Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule Type, 2021-2034
10.3.5. Asia Pacific Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channel, 2021-2034
10.3.6. Asia Pacific Trastuzumab Biosimilar Market revenue (US$ Million) by Country, 2021-2034
10.3.6.1.China
10.3.6.2.India
10.3.6.3.Japan
10.3.6.4.Australia
10.3.6.5.Rest of Asia Pacific
10.4. Latin America
10.4.1. Latin America Trastuzumab Biosimilar Market revenue (US$ Million) by product, (US$ Million)
10.4.2. Latin America Trastuzumab Biosimilar Market revenue (US$ Million) by Indication Type, (US$ Million)
10.4.3. Latin America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
10.4.4. Latin America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule Type, 2021-2034
10.4.5. Latin America Trastuzumab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channel, 2021-2034
10.4.6. Latin America Trastuzumab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2021-2034
10.4.6.1.Brazil
10.4.6.2.Rest of Latin America
10.5. MEA
10.5.1. MEA revenue Trastuzumab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2021-2034
10.5.1.1.GCC Countries
10.5.1.2.South Africa
10.5.1.3.Rest of MEA
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Amgen Inc.
11.2.2. Pfizer Inc.
11.2.3. Samsung Bioepis Co., Ltd.
11.2.4. Merck & Co.
11.2.5. Biocon Limited
11.2.6. Mylan Inc.
11.2.7. BioXpress Therapeutics SA
11.2.8. Celltrion
11.2.9. EirGenix, Inc.
11.2.10.Teva Pharmaceutical Industries Ltd.
11.2.11.ALTEOGEN Inc.
11.2.12.Apotex (Apobiologix)
11.2.13.AryoGen Pharmed
11.2.14.BIOCAD
11.2.15.Prestige BioPharma (PBP)
11.2.16.PlantForm
11.2.17.Outlook Therapeutics (Oncobiologics)
11.2.18.Shanghai CP Guojian Pharmaceutical
11.2.19.Shanghai Henlius Biotech
11.2.20.Stada Arzneimittel AG
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們